Description of the medicine: Alermizol

Astemizole *. 1- (p-Fluorobenzyl) -2 - [[1- (p-methoxyphenylethyl) -4-piperidyl] amino] benzimidazole.

Synonyms: Gismanal, Alermizol, Astelong, Hismanal, Nistamanal, Ifirab, Lembil, Stemiz, Vagran.

The blocker of H 1 -gistaminovyh receptors.

It does not bind to muscarinic and dopamine receptors, it has weak antiserotonin activity. Does not have a sedative effect, does not potentiate the effects of hypnotics and sedatives, analgesics.

It is characterized by high activity and duration of action. When ingested quickly absorbed. The peak concentration in blood plasma is observed 1 to 4 hours after administration. Excretion from the body lasts up to 10 - 14 days.

Partially unchanged astemizole and its metabolites are excreted mainly with feces. Through the blood-brain barrier does not penetrate.

Bioavailability of astemizole decreases when taken with food.

Applied for the treatment of seasonal rhinitis (pollinosis), allergic conjunctivitis, skin itching and other allergic manifestations.

Assign adults and children over 12 years in a dose of 10 mg (0.01 g) 1 time per day on an empty stomach. If necessary, increase the daily dose to 30 mg. The maximum duration of the drug is 7 days.

Children aged 6 to 12 years are given 5 mg per day (1/2 tablet); If necessary, 15 mg per day, maximum for 7 days. Children under 6 years - 2 mg (2 ml of suspension) per 10 kg of body weight.

When taking astemizola, side effects are usually not observed, but it is possible to increase appetite with an increase in body weight.

At pregnancy a preparation do not appoint or nominate.

Astemizole does not affect the action of corticosteroids, antibiotics, sulfonamides, diuretics, analgesics, cardiovascular drugs.

Forms of release: tablets of 0.01 g (10 mg) in a package of 10 pieces; A suspension containing in 5 ml (1 teaspoon) of 0.005 g (5 mg) of the preparation, in 50 ml vials.

Storage: List B.